These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
472 related articles for article (PubMed ID: 21968130)
1. Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. Patel J; Everly M; Chang D; Kittleson M; Reed E; Kobashigawa J J Heart Lung Transplant; 2011 Dec; 30(12):1320-6. PubMed ID: 21968130 [TBL] [Abstract][Full Text] [Related]
2. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction. Stuckey LJ; Kamoun M; Chan KM Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499 [TBL] [Abstract][Full Text] [Related]
4. HLA desensitization with bortezomib in a highly sensitized pediatric patient. May LJ; Yeh J; Maeda K; Tyan DB; Chen S; Kaufman BD; Bernstein D; Rosenthal DN; Hollander SA Pediatr Transplant; 2014 Dec; 18(8):E280-2. PubMed ID: 25174602 [TBL] [Abstract][Full Text] [Related]
5. Management of children undergoing cardiac transplantation with high Panel Reactive Antibodies. Asante-Korang A; Jacobs JP; Ringewald J; Carapellucci J; Rosenberg K; McKenna D; McCormack J; Wilmot I; Gjeldum A; Lopez-Cepero M; Sleasman J Cardiol Young; 2011 Dec; 21 Suppl 2():124-32. PubMed ID: 22152539 [TBL] [Abstract][Full Text] [Related]
6. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection. Hardinger KL; Murillo D Clin Transpl; 2011; ():401-8. PubMed ID: 22755438 [TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibition by bortezomib: effect on HLA-antibody levels and specificity in sensitized patients awaiting renal allograft transplantation. Guthoff M; Schmid-Horch B; Weisel KC; Häring HU; Königsrainer A; Heyne N Transpl Immunol; 2012 Jun; 26(4):171-5. PubMed ID: 22326708 [TBL] [Abstract][Full Text] [Related]
8. Late antibody-mediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody. Hodges AM; Lyster H; McDermott A; Rice AJ; Smith JD; Rose ML; Banner NR Transplantation; 2012 Mar; 93(6):650-6. PubMed ID: 22245878 [TBL] [Abstract][Full Text] [Related]
9. Desensitization protocol using bortezomib for highly sensitized patients awaiting heart or lung transplants. Weston M; Rolfe M; Haddad T; Lopez-Cepero M Clin Transpl; 2009; ():393-9. PubMed ID: 20524304 [TBL] [Abstract][Full Text] [Related]
10. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience. Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614 [TBL] [Abstract][Full Text] [Related]
11. Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. Waiser J; Budde K; Schütz M; Liefeldt L; Rudolph B; Schönemann C; Neumayer HH; Lachmann N Nephrol Dial Transplant; 2012 Mar; 27(3):1246-51. PubMed ID: 21852274 [TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibitor treatment of antibody-mediated allograft rejection. Woodle ES; Alloway RR; Girnita A Curr Opin Organ Transplant; 2011 Aug; 16(4):434-8. PubMed ID: 21753709 [TBL] [Abstract][Full Text] [Related]
13. Four-year allograft survival in a highly sensitized combined liver-kidney transplant patient despite unsuccessful anti-HLA antibody reduction with rituximab, splenectomy, and bortezomib. Koch M; Gräser C; Lehnhardt A; Pollok JM; Kröger N; Verboom M; Thaiss F; Eiermann T; Nashan B Transpl Int; 2013 Aug; 26(8):e64-8. PubMed ID: 23672514 [TBL] [Abstract][Full Text] [Related]